Vanderbilt Ingram Cancer Center

Amid the intense discussions around head and neck cancer (HNC) treatment and survivorship planning, sexuality — an important quality of life issue — may understandably not be discussed. When and in what manner do patients with HNC want to talk about the impact the disease may have on their sexuality?

The Vanderbilt-Ingram Cancer Center Neurofibromatosis (NF) Clinic has joined the Children’s Tumor Foundation NF Clinic Network.

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center (VICC) have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC).

Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

Clinicians, investigators and cancer patients now have access to a new online search tool that provides more detailed information about clinical research trials available for cancer patients.

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

Members of the Vanderbilt University Medical Center (VUMC) community and others whose lives and careers have been influenced by legendary cancer investigator, educator and administrator Harold (Hal) Moses, M.D., have endowed the Linda and Harold L. Moses, M.D. Career Development Fund.